Valuation: Evolus, Inc.

Market Cap 377M 330M 304M 280M 529M 36.34B 540M 3.64B 1.43B 17.8B 1.42B 1.39B 61.27B P/E 2026 *
-11.5x
P/E 2027 * -39.1x
Enterprise Value 504M 441M 407M 375M 707M 48.57B 722M 4.86B 1.91B 23.79B 1.89B 1.85B 81.89B EV / Sales 2026 *
1.53x
EV / Sales 2027 * 1.31x
Free-Float
83.36%
Yield 2026 *
-
Yield 2027 * -
1 day+1.78%
1 week-13.31%
Current month-17.44%
1 month-14.99%
3 months+22.17%
6 months+10.19%
Current year-13.83%
1 week 5.52
Extreme 5.52
6.62
1 month 5.52
Extreme 5.52
7.32
Current year 3.86
Extreme 3.86
7.32
1 year 3.86
Extreme 3.86
10.2
3 years 3.86
Extreme 3.86
17.82
5 years 3.86
Extreme 3.86
17.82
10 years 2.85
Extreme 2.85
39.5
Manager TitleAgeSince
Chief Executive Officer 48 05/05/2018
Director of Finance/CFO 48 07/09/2025
Chief Operating Officer - 31/08/2022
Director TitleAgeSince
Chairman 63 31/12/2017
Director/Board Member 71 11/02/2018
Director/Board Member 48 05/05/2018
Date Insider Type Main position Quantity % Market Cap.
20/03/26 Sell

Chief Executive Officer

13,669 0.0211%
20/03/26 Sell

Chief Technology Officer

3,119 0.0048%
16/03/26 Fiscal year

Chief Technology Officer

47,604 0.0736%
Change 5-day change 1-year change 3-year change Capi.($)
+1.78%-13.31%-38.65%-21.72% 377M
+0.85%-0.80%+54.84%+163.70% 1,051B
+1.23%-1.53%+55.26%+59.07% 609B
+0.04%+2.58%+32.96%+88.75% 450B
+0.78%-0.71%+30.04%+24.61% 330B
+1.41%+0.58%+33.92%+47.20% 284B
-0.27%-1.87%+22.13%+23.47% 263B
-1.76%+2.37%-22.19%-38.45% 223B
-1.42%+0.80%+22.81%+60.77% 198B
-1.48%+3.43%+23.42%+73.31% 167B
Average +0.07%-0.85%+21.45%+48.07% 357.54B
Weighted average by Cap. +0.22%+0.02%+37.74%+81.48%

Financials

2026 *2027 *
Net sales 330M 289M 266M 246M 463M 31.82B 473M 3.19B 1.25B 15.59B 1.24B 1.21B 53.65B 388M 339M 313M 288M 543M 37.33B 555M 3.74B 1.47B 18.28B 1.46B 1.42B 62.94B
Net income -33.31M -29.11M -26.86M -24.76M -46.66M -3.21B -47.7M -321M -126M -1.57B -125M -122M -5.41B -10.56M -9.23M -8.52M -7.85M -14.8M -1.02B -15.13M -102M -40.04M -498M -39.66M -38.79M -1.71B
Net Debt 127M 111M 102M 94.4M 178M 12.23B 182M 1.22B 481M 5.99B 477M 466M 20.62B 132M 115M 106M 98.12M 185M 12.71B 189M 1.27B 500M 6.23B 496M 485M 21.43B
Logo Evolus, Inc.
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Employees
350
Date Price Change Volume
17/07/26 US$5.730 +1.78% 457,993
16/07/26 US$5.630 -5.54% 1,194,659
15/07/26 US$5.960 -4.94% 1,117,419
14/07/26 US$6.270 -3.83% 567,719
13/07/26 US$6.520 -1.36% 1,316,602
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.730USD
Average target price
14.67USD
Spread / Average Target
+155.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EOLS Stock